Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Pyxis Oncology, Inc. PYXS
$3.29
+$0.27 (8.22%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
104655098.00000000
-
week52high
6.92
-
week52low
1.10
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-3.58000000
-
Last Dividend
0.00000000
-
Next Earnings Date
22 мар 2023 г. в 10:45
Описание компании
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Jefferies | Buy | 02 ноя 2021 г. | |
| Credit Suisse | Outperform | 02 ноя 2021 г. | |
| B of A Securities | Neutral | 02 ноя 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Yanchik Connealy Pamela | A | 384510 | 43493 | 03 янв 2023 г. |
| Feingold Jay | A | 520542 | 53931 | 03 янв 2023 г. |
| Sullivan Lara | A | 1452320 | 95684 | 03 янв 2023 г. |
| HUMPHREY RACHEL | A | 236220 | 236220 | 11 авг 2022 г. |
| Chin Mark | D | 0 | 1745761 | 21 апр 2022 г. |
| Yanchik Connealy Pamela | A | 341017 | 93493 | 14 апр 2022 г. |
| Sullivan Lara | A | 1356636 | 315273 | 14 апр 2022 г. |
| Feingold Jay | A | 466611 | 115931 | 14 апр 2022 г. |
| Lewis-Hall Freda C | A | 66831 | 66831 | 31 мар 2022 г. |
| Cline Darren S | A | 76831 | 66831 | 31 мар 2022 г. |
Новостная лента
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference
GlobeNewsWire
28 июн 2022 г. в 06:35
CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, today announced that the Company will present at the H.C. Wainwright Preclinical Cancer Drug Discovery - Antibody Drug Conjugates (ADCs) virtual conference. The pre-recorded presentation given by Lara Sullivan, M.D., President and Chief Executive Officer, and Jay Feingold, M.D., Ph.D., Chief Medical Officer, will be available on-demand at 9:00 a.m. ET on Wednesday, June 29, 2022.
Pyxis Oncology Announces Presentations at Upcoming Investor Conferences
GlobeNewsWire
19 мая 2022 г. в 06:35
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, and members of the management team will present at the following upcoming investor conferences:
Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022
GlobeNewsWire
22 мар 2022 г. в 06:35
CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset, multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced it will host a conference call and live webcast on Tuesday, March 29, 2022 at 8:00 a.m. ET to discuss recent corporate updates.
Pyxis Oncology to Present at the Jefferies London Healthcare Conference
GlobeNewsWire
10 ноя 2021 г. в 08:00
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), today announced that management will present at and host one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021. The presentation will be available on-demand for attendees during the virtual conference beginning on November 18, 2021. A replay of the presentation will be available on the Events and Presentation page on Pyxis Oncology's website following the conference's conclusion.